Unani formulation (Sharbat-e-Toot Siyah) in Warm-e-Halaq Muzmin(Chronic Pharyngitis) patients

Comparative clinical evaluation of Sharbat-e-Toot Siyah and its sugarfree dosage form in the management of Warm-e-Halaq Muzmin (Chronic Pharyngitis) - WHM

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/069725

Enrollment

Registered

2024-07-01

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J312- Chronic pharyngitis

Interventions

Intervention1: Sharbat-e-Toot Siyah (Sugar free): 25ml of sugar free Sharbat-e-Toot Siyah will be given orally twice a day for 6 weeks Control Intervention1: Sharbat-e-Toot Siyah: 25ml of Sharbat-e-To

Eligibility

Inclusion criteria

Inclusion criteria: 1) Diagnosed patients of chronic pharyngitis (Pharyngitis more than 3 months) presenting with all OR more than three of the following signs and symptoms Sore throat Dysphagia Foreign body sensation Burning sensation Cough Hoarseness of voice Pharyngeal itching Posterior pharyngeal wall hypertrophy oedema redness

Exclusion criteria

Exclusion criteria: 1) Age below 18 and above 65 years 2) Pregnant and lactating women 3) Congenital malformations of oropharynx 4) Diabetes mellitus 5) Oral candidiasis 6) Unwilling to participate in the study 7) Epiglottitis, Thyroiditis 8) Retropharyngeal abscess/peritonsillar abscess 9) Dental Sepsis 10) Carcinoma of throat 11) History of previous use of corrosives 12) Pts with Chronic liver, kidney or heart disease 13) Pts suffering from psychiatric disorders 14) History of seizures, severe HTN 15) Pts having carcinoma and terminal illness 16) Pts taking antibiotics for the current illness for last one week 17) Pts on regular steroid inhalers: MDI (Metered Dose Inhalers)

Design outcomes

Primary

Measure	Time frame
1. Improvement in Subjective Parameters i.e. symptoms to be assessed on Visual Analogue Scale (0 to 100 mm) Sore throat Dysphagia Foreign body sensation Burning sensation Cough Hoarseness of voice Pharyngeal itching 2. Improvement in Objective Parameters i.e. PHARYNGOSCOPY will be used to analyse the signs of Chronic Pharyngitis [Grading on Likert Scale (4 point)] on following Pharyngeal Signs Hypertrophy Oedema Redness Timepoint: Baseline and 6 weeks	—

Measure

Time frame

1. Improvement in Subjective Parameters i.e. symptoms to be assessed on Visual Analogue Scale (0 to 100 mm) Sore throat Dysphagia Foreign body sensation Burning sensation Cough Hoarseness of voice Pharyngeal itching 2. Improvement in Objective Parameters i.e. PHARYNGOSCOPY will be used to analyse the signs of Chronic Pharyngitis [Grading on Likert Scale (4 point)] on following Pharyngeal Signs Hypertrophy Oedema Redness Timepoint: Baseline and 6 weeks

—

Secondary

Measure	Time frame
Improvement in quality of life (QoL)Timepoint: 0 & 6 weeks	—

Countries

India

Contacts

Public ContactDr Azhar Jabin

Jamia Hamdard

shaziajilani@jamiahamdard.ac.in9718764154

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026